ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
With momentum building in its Alzheimer’s disease research, Eli Lilly and Company says it will split its Lilly Bio-Medicines division into neuroscience and immunology groups. The neuroscience unit will be responsible for pain and neurodegeneration drugs that have been launched or are in Phase 3 trials, including the potential Alzheimer’s treatment donanemab. In immunology, Lilly recently announced positive Phase 3 trials for mirikizumab for ulcerative colitis and lebrikizumab for atopic dermatitis. Lilly also announced the merger of Loxo Oncology, which it acquired in 2019, with its oncology unit.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X